Cost-effectiveness of interferon for high-risk (stage III) melanoma patients

被引：1
|
作者：
Guillem, V
Alvarez-Mon, M
Camacho, F
Diaz-Perez, JL
Diaz-Rubio, E
Gonzalez-Larriba, JL
Lopez-Lopez, JJ
Moreno, JA
Serrano, S
Toribio, J
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81927-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1513
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain
    González-Larriba, JL
    Serrano, S
    Alvarez-Mon, M
    Camacho, F
    Casado, MA
    Díaz-Pérez, JL
    Díaz-Rubio, E
    Fosbrook, L
    Guillem, V
    López-López, JJ
    Moreno-Nogueira, JA
    Toribio, J
    [J]. EUROPEAN JOURNAL OF CANCER, 2000, 36 (18) : 2344 - 2352
  • [2] Cost-effectiveness (CE) analysis of interferon-alpha in high-risk melanoma patients
    Ding, M
    Xing, Y
    Shih, T
    Cox, D
    Cantor, S
    Cormier, J
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 221 - 221
  • [3] Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States
    Bensimon, Arielle G.
    Zhou, Zheng-Yi
    Jenkins, Madeline
    Song, Yan
    Gao, Wei
    Signorovitch, James
    Krepler, Clemens
    Liu, Frank Xiaoqing
    Wang, Jingshu
    Aguiar-Ibanez, Raquel
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 981 - 993
  • [4] Economic analysis of interferon for high-risk (stage III) melanoma patients.
    González-Larriba, JL
    Alvarez-Mon, M
    Camacho, F
    Casado, MA
    Díaz-Pérez, JL
    Díaz-Rubio, E
    Guillem, V
    López-López, JJ
    Moreno, JA
    Serrano, S
    Toribio, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S50 - S50
  • [5] A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1373 - 1379
  • [6] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
    Salans, Mia
    Courtney, Patrick Travis
    Yip, Anthony
    Murphy, James D.
    [J]. CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
  • [7] Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.
    Pumpalova, Yoanna S.
    Rogers, Alexandra M.
    Tan, Sarah Xinhui
    Herbst, Candice-Lee
    Ruff, Paul
    Neugut, Alfred I.
    Hur, Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa
    Tan, Sarah Xinhui
    Pumpalova, Yoanna
    Rogers, Alexandra M. M.
    Bhatt, Kishan
    Herbst, Candice-lee
    Ruff, Paul
    Neugut, Alfred I. I.
    Hur, Chin
    [J]. CANCER MEDICINE, 2023, 12 (14): : 15515 - 15529
  • [9] Cost-effectiveness of antifungal strategies in high-risk neutropenic patients
    Schwarzinger, Michael
    Baillot, Sylvain
    Beauchamp, Celine
    Maury, Sebastien
    Pautas, Cecile
    Vekhoff, Anne
    Farhat, Hassan
    Suarez, Felipe
    Kuentz, Mathieu
    Cordonnier, Catherine
    [J]. BLOOD, 2007, 110 (11) : 153B - 153B
  • [10] SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF PALIVIZUMAB IN HIGH-RISK PATIENTS
    Paladio Duran, N.
    Garcia-Altes, A.
    Pons Rafols, J. M.
    Tebe Cordomi, C.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A432 - A432
12345